Expect positive stock reaction on this first-line Phase III win. Monitor for regulatory submission in China and potential label expansion.
Drug in focus
HCM drug pipeline →ORPATHYS
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 31 $12.12entry
- T+1 · 3mo ago −1.73%α −1.05% · $11.91
- T+5 · 2mo ago +14.52%α +14.66% · $13.88
- T+20 · 7w ago +16.75%α +16.94% · $14.15
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) significantly improves progression-free survival vs TAGRISSO alone in first-line MET-overexpressing EGFR-mutated NSCLC in China. The combination also demonstrated encouraging overall survival benefit. This expands the clinical value of the all-oral combination into the first-line setting, building on prior SACHI and SAFFRON trials. The data will be submitted to regulatory authorities for label expansion in China.
Key Facts
- SANOVO Phase III met primary endpoint: statistically significant and clinically meaningful PFS improvement vs TAGRISSO alone in both high MET and ITT populations
- Encouraging OS benefit observed as secondary endpoint; trial continues follow-up
- Safety profile consistent with known profiles of each medicine; no new safety findings
- 326 treatment-naïve patients randomized 1:1 to ORPATHYS+TAGRISSO vs TAGRISSO+placebo
- ORPATHYS jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca
- ORPATHYS+TAGRISSO already approved in China for later-line MET-amplified EGFR-mutated NSCLC based on SACHI trial
Financial Impact
Potential label expansion into first-line NSCLC in China significantly expands addressable patient population for ORPATHYS+TAGRISSO combination; no specific revenue figures provided in filing
Risk Factors
- Regulatory approval for first-line indication not guaranteed; data review timeline uncertain
- Competition from other MET-targeted therapies and EGFR-TKI combinations
- OS data immature; final OS readout may differ from interim encouraging trend
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000055 |
| Document: hcm-20260831x6k.htm | 0001648257-26-000055 |
| Document: 0001648257-26-000055-index-headers.html | 0001648257-26-000055 |
| Document: 0001648257-26-000055-index.html | 0001648257-26-000055 |
| Document: 0001648257-26-000055.txt | 0001648257-26-000055 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers